253 related articles for article (PubMed ID: 27128782)
1. Intensity of adjuvant chemotherapy regimens and grade III-V toxicities among elderly stage III colon cancer patients.
van Erning FN; Razenberg LG; Lemmens VE; Creemers GJ; Pruijt JF; Maas HA; Janssen-Heijnen ML
Eur J Cancer; 2016 Jul; 61():1-10. PubMed ID: 27128782
[TBL] [Abstract][Full Text] [Related]
2. CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer.
Loree JM; Mulder KE; Ghosh S; Spratlin JL
Clin Colorectal Cancer; 2014 Sep; 13(3):172-7. PubMed ID: 24630275
[TBL] [Abstract][Full Text] [Related]
3. Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre, retrospective, chart review study.
Sha A; Abadi S; Gill S
J Oncol Pharm Pract; 2018 Oct; 24(7):501-506. PubMed ID: 28714378
[TBL] [Abstract][Full Text] [Related]
4. Retrospective comparison of CAPOX and FOLFOX dose intensity, toxicity, and clinical outcomes in the treatment of metastatic colon cancer.
Loree JM; Mulder KE; Ghosh S; Spratlin JL
J Gastrointest Cancer; 2014 Jun; 45(2):154-60. PubMed ID: 24408272
[TBL] [Abstract][Full Text] [Related]
5. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
André T; Meyerhardt J; Iveson T; Sobrero A; Yoshino T; Souglakos I; Grothey A; Niedzwiecki D; Saunders M; Labianca R; Yamanaka T; Boukovinas I; Vernerey D; Meyers J; Harkin A; Torri V; Oki E; Georgoulias V; Taieb J; Shields A; Shi Q
Lancet Oncol; 2020 Dec; 21(12):1620-1629. PubMed ID: 33271092
[TBL] [Abstract][Full Text] [Related]
6. Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer.
Loree JM; Sha A; Soleimani M; Kennecke HF; Ho MY; Cheung WY; Mulder KE; Abadi S; Spratlin JL; Gill S
Clin Colorectal Cancer; 2018 Jun; 17(2):156-163. PubMed ID: 29486916
[TBL] [Abstract][Full Text] [Related]
7. Population-Based Cost-Minimization Analysis of CAPOX Versus Modified FOLFOX6 in the Adjuvant Treatment of Stage III Colon Cancer.
Ho MY; Chang AY; Ruan JY; Cheung WY
Clin Colorectal Cancer; 2016 Jun; 15(2):158-63. PubMed ID: 26524925
[TBL] [Abstract][Full Text] [Related]
8. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
Sobrero A; Lonardi S; Rosati G; Di Bartolomeo M; Ronzoni M; Pella N; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Zagonel V; Maiello E; Barni S; Rulli E; Labianca R;
J Clin Oncol; 2018 May; 36(15):1478-1485. PubMed ID: 29620994
[TBL] [Abstract][Full Text] [Related]
9. A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6/CAPOX for stage III colon cancer treatment after D2/D3 lymphadenectomy.
Yoshimatsu K; Ishibashi K; Koda K; Yokomizo H; Oda N; Oshiro M; Kato H; Oya M; Nakajima H; Ooki S; Maekawa H; Matsunami T; Tsubaki M; Yamada T; Kobayashi M; Tanakaya K; Yokoyama M; Ishida H
Surg Today; 2019 Jun; 49(6):498-506. PubMed ID: 30953164
[TBL] [Abstract][Full Text] [Related]
10. Real-world tolerance and outcomes of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer-Does dose intensity matter?
Yoon R; Wilkinson K; Gabriel G; Kadaan N; Roberts T; Lim S; Asghari R; Lee CS; Chua W; Ng W
Asia Pac J Clin Oncol; 2024 Feb; 20(1):63-70. PubMed ID: 37211922
[TBL] [Abstract][Full Text] [Related]
11. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Grothey A; Sobrero AF; Shields AF; Yoshino T; Paul J; Taieb J; Souglakos J; Shi Q; Kerr R; Labianca R; Meyerhardt JA; Vernerey D; Yamanaka T; Boukovinas I; Meyers JP; Renfro LA; Niedzwiecki D; Watanabe T; Torri V; Saunders M; Sargent DJ; Andre T; Iveson T
N Engl J Med; 2018 Mar; 378(13):1177-1188. PubMed ID: 29590544
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study.
Osawa H; Handa N; Minakata K
Oncol Res; 2014; 22(5-6):325-31. PubMed ID: 26629945
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
[TBL] [Abstract][Full Text] [Related]
14. The impact of age on first-line systemic therapy in patients with metachronous metastases from colorectal cancer.
Razenberg LG; van Erning FN; Pruijt HF; Ten Tije AJ; van Riel JM; Creemers GJ; Lemmens VE
J Geriatr Oncol; 2017 Jan; 8(1):37-43. PubMed ID: 27659548
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
16. A Feasibility Study of Capecitabine and Oxaliplatin for Patients with Stage II/III Colon Cancer -ACTOR Study.
Suenaga M; Akiyoshi T; Shinozaki E; Fujimoto Y; Matsusaka S; Konishi T; Nagayama S; Fukunaga Y; Kawakami K; Yokokawa T; Sugisaki T; Ueno M; Yamaguchi T
Anticancer Res; 2018 Mar; 38(3):1741-1747. PubMed ID: 29491111
[TBL] [Abstract][Full Text] [Related]
17. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Porschen R; Arkenau HT; Kubicka S; Greil R; Seufferlein T; Freier W; Kretzschmar A; Graeven U; Grothey A; Hinke A; Schmiegel W; Schmoll HJ;
J Clin Oncol; 2007 Sep; 25(27):4217-23. PubMed ID: 17548840
[TBL] [Abstract][Full Text] [Related]
18. Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy.
van Erning FN; Janssen-Heijnen ML; Creemers GJ; Pruijt JF; Maas HA; Lemmens VE
Int J Cancer; 2017 Jan; 140(1):224-233. PubMed ID: 27615021
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Schmoll HJ; Cartwright T; Tabernero J; Nowacki MP; Figer A; Maroun J; Price T; Lim R; Van Cutsem E; Park YS; McKendrick J; Topham C; Soler-Gonzalez G; de Braud F; Hill M; Sirzén F; Haller DG
J Clin Oncol; 2007 Jan; 25(1):102-9. PubMed ID: 17194911
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
